Table 2.

Associations between IGF variables and HGCIN in models controlling for different variables

IGF variable and levelsCases, n (%)Controls, n (%)OR (95% CI)
Ptrend*
Age adjustedAge, ethnicity, sexual activity, and mutual IGF-I and IGFBP-3 adjustedAge, ethnicity, sexual activity, mutual IGF-I and IGFBP-3, and HPV status adjusted§
IGF-I (quartiles), ng/mL
    Q1 (<239.0)103 (31.31)156 (25.12)1.00 (reference)1.00 (reference)1.00 (reference)
    Q2 (239.0-311.0)110 (33.43)155 (24.96)0.92 (0.64-1.34)0.90 (0.60-1.33)0.89 (0.48-1.66)
    Q3 (311.0-382.0)58 (17.63)155 (24.96)0.47 (0.31-0.71)0.39 (0.25-0.62)0.47 (0.23-0.94)
    Q4 (>382.0)58 (17.63)155 (24.96)0.46 (0.30-0.72)0.39 (0.24-0.65)0.40 (0.19-0.87)0.007
IGFBP-3 (quartiles), ng/mL
    Q1 (<4,577.3)76 (23.10)155 (24.96)1.00 (reference)1.00 (reference)1.00 (reference)
    Q2 (4,577.3-5,088.8)91 (27.66)156 (25.12)1.16 (0.79-1.70)1.42 (0.95-2.14)1.27 (0.67-2.40)
    Q3 (5,088.8-5,678.2)93 (28.27)155 (24.96)1.21 (0.83-1.78)1.60 (1.05-2.43)1.57 (0.81-3.01)
    Q4 (>5,678.2)69 (20.97)155 (24.96)0.93 (0.62-1.39)1.40 (0.88-2.18)1.15 (0.57-2.31)0.666
  • * P value for dose-response trend for the relation between IGF variable and outcome in the model adjusted for age, ethnicity, sexual activity, mutual IGF-I and IGFBP-3, and HPV status.

  • Analyses adjusted for age group (<25, 25-29, 30-34, 35-39, 40-44, 45-49, and ≥50 y).

  • Analyses adjusted for age group, ethnicity (French Canadian, English Canadian, Other), sexual activity defined with age at first intercourse (<16, 16-17, 18, >19 y), number of sexual partners (1, 2-4, 5-8, and >8 partners), and mutual adjustment for IGF-I and IGFBP-3 according to the quartiles presented in the table.

  • § Analyses adjusted also for HPV status (negative, low-risk HPV only, high-risk HPV except HPV-16/HPV-18, and HPV-16/HPV-18).